E Arranz-Marquez, MA Teus, MA Saornil, MC … - American journal of ophthalmology, 2004 - Elsevier Iris biopsies of eyes treated with latanoprost were analyzed (all had a
photographically documented increase in iris pigmentation) plus control eyes
(untreated with prostanoids) using optical microscopy. patient or study ... Cited by 12 - Related articles - All 12 versions
T Chiba, K Kashiwagi, K Ishijima, M Furuichi, … - Japanese journal of ophthalmology, 2004 - Springer Latanoprost, a prostaglandin (PG)-related ophthalmic solution, is widely used
because, unlike β-blockers, it has few systemic adverse effects on the
cardiovascular or respiratory system; however, this ophthalmic solution has Cited by 12 - Related articles - All 4 versions
DM Albert, RE Gangnon, ML Zimbric, CM … - Archives of Ophthalmology, 2004 - Am Med Assoc Results Specimens were received from 449 patients with a history of latanoprost
treatment and 142 patients who had no history of treatment with latanoprost or
other prostaglandin analogues. No evidence of malignant or premalignant ... Cited by 11 - Related articles - BL Direct - All 5 versions
I Grierson, M Jonsson, K Cracknell - Japanese journal of ophthalmology, 2004 - Springer Abstract Latanoprost is a prostaglandin analogue with well-established efficacy
in the treatment of open-angle glaucoma and ocular hypertension. Once-daily
administration of this drug for up to 5 years is generally well tolerated ... Cited by 9 - Related articles - All 3 versions
KPB Cracknell, I Grierson, P Hogg - Ophthalmology, 2007 - Elsevier Iridectomy specimens from LIID cases were collected from patients undergoing
trabeculectomy, whereas before surgery they had been on topical latanoprost and
there was clear evidence of iris color change from the treating ... Cited by 7 - Related articles - All 24 versions
L Rossetti, S Gandolfi, C Traverso, P … - Journal of Glaucoma, 2006 - journals.lww.com Journal of Glaucoma. Wolters Kluwer Health | Lippincott
Williams & Wilkins. All Issues. ... Cited by 2 - Related articles - All 16 versions
E Arranz-Marquez, MA Teus - Expert Opin. Drug Saf., 2008 - informahealthcare.com Background: Prostanoids are the newest pharmacologic group of ocular hypotensive
drugs for clinical management of glaucoma. The group includes four chemical
compounds structurally derived from naturally-occurring prostaglandin (PG) ... Cited by 1 - Related articles - All 6 versions
HHA Russ, VP Costa, FM Ferreira, SR Valgas, … - Arquivos Brasileiros de Oftalmologia, 2007 - SciELO Brasil PG analogues increase uveoscleral outflow and may reduce intraocular pressure up
to 40% of its initial value. Systemic side effects induced by topical PG
analogues are rare. On the other hand, iris hyperpigmentation, excessive ... Cited by 2 - Related articles - Cached - All 6 versions
H Borgen, P Bours, SD Wolthusen - Proceedings of the Third International Conference on …, 2009 - Springer Abstract. Many applications of ocular biometrics require long-term stability,
yet only limited data on the effects of disease and aging on the error rates of
ocular biometrics is currently available. Based on patholo- gies simulated ... Cited by 1 - Related articles - All 2 versions
